Skip to main
CODX
CODX logo

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc. benefits from its unique international footprint, which includes joint ventures in India and the Kingdom of Saudi Arabia, alongside strong manufacturing capabilities in the United States, enabling the company to enhance the accessibility of its high-quality molecular diagnostics. The company's proprietary technology and patented design algorithms facilitate scalability in operations, which positions Co-Diagnostics favorably within the growing molecular diagnostics market. Despite concerns regarding potential dilutive capital raises, the overall strategic partnerships and innovative capabilities suggest a robust foundation for future growth and operational success.

Bears say

Co-Diagnostics Inc. has experienced a significant downward revision in its price target, shifting from $10.00 to $3.00, which indicates increased skepticism about its financial prospects despite being higher than the recent closing price of $0.43. The company's cash position of $11 million, coupled with projected quarterly expenditures of $5 to $7 million, raises concerns about potential liquidity issues and the risk of entering a downward financing spiral. Overall, the combination of reduced price expectations and alarming cash burn rates contribute to a negative outlook on the company's stock.

Co-Diagnostics (CODX) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Buy based on their latest research and market trends.

According to 2 analysts, Co-Diagnostics (CODX) has a Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.